The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has introduced the Global Radiopharmaceutical Trial Finder, an AI-powered platform designed to connect patients, physicians, and researchers to instantly discover radiopharmaceutical clinical trials, this initiative directly supports SNMMI's mission of improving patient access to nuclear medicine procedures.
Developed by Ancora.ai and hosted on the SNMMI website, the Trial Finder provides real-time data from ClinicalTrials.gov and three other international registries, refreshed daily, without storing or selling personal information.
Clinical trials are essential for developing new radiopharmaceuticals that can diagnose, treat, and even cure cancer. Despite 84% of patients indicating willingness to participate in trials if recommended by their physician, only 3% to 5% of eligible adult cancer patients enroll. The platform aims to address this gap by simplifying trial discovery.
Patients can select by condition and ZIP code, the Trial Finder then asks specific questions about their disease stage and past treatments to create a customized list of eligible trials. Each result indicates the strength of the match and the distance to the trial site. Physicians can use the same interface to identify suitable trials for patients. Researchers can refine searches using parameters such as trial phase, type of radionuclide, and target, and access Quick Charts showing trial types, locations, and sponsors.
The Global Radiopharmaceutical Trial Finder shows how AI can make nuclear medicine more accessible. By using this tool, patients and their referring providers can easily find life-saving care.
Click here to read the original press release.
More News in this Theme
